WO2004091507A3 - Optimal polyvalent vaccine for cancer - Google Patents

Optimal polyvalent vaccine for cancer Download PDF

Info

Publication number
WO2004091507A3
WO2004091507A3 PCT/US2004/011122 US2004011122W WO2004091507A3 WO 2004091507 A3 WO2004091507 A3 WO 2004091507A3 US 2004011122 W US2004011122 W US 2004011122W WO 2004091507 A3 WO2004091507 A3 WO 2004091507A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
polyvalent vaccine
cell line
provides
optimal
Prior art date
Application number
PCT/US2004/011122
Other languages
French (fr)
Other versions
WO2004091507A2 (en
Inventor
Philip O Livingston
Govindaswami Ragupathi
Original Assignee
Sloan Kettering Inst Cancer
Philip O Livingston
Govindaswami Ragupathi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Philip O Livingston, Govindaswami Ragupathi filed Critical Sloan Kettering Inst Cancer
Priority to JP2006509902A priority Critical patent/JP2006522828A/en
Priority to CA002521812A priority patent/CA2521812A1/en
Priority to EP04759415A priority patent/EP1615614A4/en
Publication of WO2004091507A2 publication Critical patent/WO2004091507A2/en
Priority to US11/246,752 priority patent/US20060035267A1/en
Publication of WO2004091507A3 publication Critical patent/WO2004091507A3/en
Priority to US12/089,302 priority patent/US20080241195A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of: a) selection of an appropriate cancer cell line; and b) detection of the expression of antigens on the surface of said cell line of the cancer, wherein the antigens expressed will be used in the polyvalent vaccine. This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of: a) selection of an appropriate cancer cell line and b) detection of the immunogenicity will be used in the polyvalent vaccine. This invention provides various uses of the identified polyvalent vaccine.
PCT/US2004/011122 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer WO2004091507A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006509902A JP2006522828A (en) 2003-04-09 2004-04-09 Optimal multivalent vaccine for cancer
CA002521812A CA2521812A1 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer
EP04759415A EP1615614A4 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer
US11/246,752 US20060035267A1 (en) 2003-04-09 2005-10-07 Optimal polyvalent vaccine for cancer
US12/089,302 US20080241195A1 (en) 2003-04-09 2006-10-06 Optimal Polyvalent Vaccine for Cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46162203P 2003-04-09 2003-04-09
US60/461,622 2003-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/246,752 Continuation-In-Part US20060035267A1 (en) 2003-04-09 2005-10-07 Optimal polyvalent vaccine for cancer

Publications (2)

Publication Number Publication Date
WO2004091507A2 WO2004091507A2 (en) 2004-10-28
WO2004091507A3 true WO2004091507A3 (en) 2005-12-15

Family

ID=33299843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011122 WO2004091507A2 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer

Country Status (4)

Country Link
EP (1) EP1615614A4 (en)
JP (1) JP2006522828A (en)
CA (1) CA2521812A1 (en)
WO (1) WO2004091507A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458242A4 (en) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer Polyvalent conjugate vaccine for cancer
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
PL1960434T3 (en) 2005-12-08 2012-12-31 Squibb & Sons Llc Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
US9125848B2 (en) 2010-06-10 2015-09-08 The Cleveland Clinic Foundation Alpha lactalbumin immunization methods
WO2013158553A1 (en) 2012-04-16 2013-10-24 The Cleveland Clinic Foundation Multivalent breast cancer vaccine
JP2015227292A (en) * 2014-05-30 2015-12-17 国立大学法人高知大学 Pancreatic cancer cell invasion metastasis inhibition vaccine
WO2017216098A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Assay and method for determining cdc eliciting antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458242A4 (en) * 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer Polyvalent conjugate vaccine for cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUSSELLI C ET AL: "Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience", J. CANCER RES. CLIN. ONCOL., vol. 127, no. 2, October 2001 (2001-10-01), pages R20 - 26, XP002259776 *
See also references of EP1615614A4 *

Also Published As

Publication number Publication date
CA2521812A1 (en) 2004-10-28
WO2004091507A2 (en) 2004-10-28
JP2006522828A (en) 2006-10-05
EP1615614A4 (en) 2007-08-22
EP1615614A2 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
WO2007044620A3 (en) Optimal polyvalent vaccine for cancer
WO2006023806A3 (en) A method and system for character recognition
AU2003236293A1 (en) Map matching method, map matching device, database for shape matching, and shape matching device
WO2004075850A3 (en) Polyvalent immunogen
WO2005098609A8 (en) A method and system for character recognition
WO2005025292A3 (en) System and method for risk based authentication
WO2005032582A8 (en) Immunogenic compositions for streptococcus pyogenes
WO2003039470A3 (en) Polyvalent immunogen of hiv
WO2003102066A3 (en) Aqueous adhesive dispersions
MXPA03007178A (en) Method, module, device and server for voice recognition.
WO2009085025A3 (en) System and method for sparql-query processing using parametrized-sparql-query in dbms-based systems
WO2004110075A3 (en) Method for selecting an operating mode based on a detected synchronization pattern
WO2001062283A3 (en) Mucosal adjuvant formulation
WO2007053165A3 (en) Virus protein microarray and uses therefor
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2004091507A3 (en) Optimal polyvalent vaccine for cancer
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2006013070A3 (en) Device for displacing a part that is connected to said device or for generating movement in said part
AU2003281558A1 (en) Probabilistic calculation element, drive method thereof, and recognition device using the same
WO2005016952A3 (en) Polyvalent immunogen
WO2005003897A3 (en) Method and apparatus for transferring a document into a folder
MXPA03007554A (en) Method and device for locating an object by means of the shape, dimensions and/or orientation thereof.
ITTO20010771A0 (en) AUTHENTICATION METHOD VIA STORAGE DEVICE.
FI20011063A0 (en) Method and apparatus for determining the position of the edge surface of pieces in a stack, e.g.
MXPA02011191A (en) Vaccines, immunotherapeutics and methods for using the same.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006509902

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2521812

Country of ref document: CA

Ref document number: 11246752

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004759415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004759415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11246752

Country of ref document: US